Daiichi Suntory, BioMarin Expand Licensing Agreement

On May 6, Daiichi Suntory Pharma (DSP) and BioMarin Pharmaceutical of California jointly announced that they have expanded the scope of their existing licensing agreement for Biopten, DSP's proprietary tetrahydrobiopterin agent for inborn errors of metabolism. Under the terms of the agreement, BioMarin Pharmaceutical will exclusively use Biopten for all indications in the global market. Currently, BioMarin Pharmaceutical is conducting Phase III clinical trials targeting hyperphenylalaninemia in the U.S. and Europe.

Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=9987)